Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Pharma symbols : Ltrn save search
Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284
Published: 2024-03-15 (Crawled : 13:30) - biospace.com/
LTRN | $5.87 -2.0% 40K
|
Health Technology
|
| O: 2.04%
H: 18.0%
C: 16.0%
lp-284 pharma trial
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ET
Published: 2024-03-11 (Crawled : 17:00) - biospace.com/
LTRN | $5.87 -2.0% 40K
|
Health Technology
|
| O: -2.06%
H: 0.74%
C: -21.98%
pharma report year financial results
Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers
Published: 2024-02-15 (Crawled : 15:00) - biospace.com/
LTRN | $5.87 -2.0% 40K
|
Health Technology
|
| O: -0.25%
H: 3.17%
C: -0.74%
pharma drug unique tumor program
Starlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS & Brain Cancers, Announces Dr. Marc Chamberlain as Chief Medical Officer
Published: 2024-01-17 (Crawled : 14:30) - biospace.com/
LTRN | $5.87 -2.0% 40K
|
Health Technology
|
| O: -0.26%
H: 0.0%
C: -4.36%
pharma medical
FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL)
Published: 2023-11-30 (Crawled : 15:00) - biospace.com/
LTRN | $5.87 -2.0% 40K
|
Health Technology
|
| O: 2.81%
H: 0.0%
C: -1.74%
lp-284 fda pharma drug candidate designation lymphomas grants
Lantern Pharma to Report Third Quarter 2023 Operating & Financial Results on November 8th, 2023 at 4:30 p.m. ET
Published: 2023-11-01 (Crawled : 14:00) - biospace.com/
LTRN | $5.87 -2.0% 40K
|
Health Technology
|
| O: -2.42%
H: 11.16%
C: 5.79%
pharma report financial results
Lantern Pharma to Present at the ThinkEquity Conference on October 19 at 1:30 p.m. ET
Published: 2023-10-10 (Crawled : 13:30) - biospace.com/
LTRN | $5.87 -2.0% 40K
|
Health Technology
|
| O: 0.65%
H: 9.62%
C: 9.62%
pharma conference
Lantern Pharma Announces Publication in Clinical Cancer Research Highlighting the Enhanced Efficacy of LP-184 in Glioblastoma
Published: 2023-10-03 (Crawled : 19:00) - biospace.com/
LTRN | $5.87 -2.0% 40K
|
Health Technology
|
| O: 3.35%
H: 0.0%
C: -11.21%
lp-184 pharma cancer publication research glioblastoma
Lantern Pharma Announces First Patient Dosed in the Phase 1 Study for LP-184 in Advanced Solid Tumors
Published: 2023-09-25 (Crawled : 15:00) - biospace.com/
LTRN | $5.87 -2.0% 40K
|
Health Technology
|
| O: 0.18%
H: 6.01%
C: -4.1%
lp-184 pharma tumors study
Lantern Pharma Receives IND Clearance from FDA Enabling Phase 1 Initiation for Drug Candidate LP-284 in Non-Hodgkin’s Lymphomas
Published: 2023-09-18 (Crawled : 23:00) - biospace.com/
LTRN | $5.87 -2.0% 40K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -3.69%
lp-284 fda pharma drug candidate clearance enabling lymphomas
Lantern Pharma to Present Data Highlighting the Anti-Tumor Potency of Drug Candidate LP-284 in Non-Hodgkin’s Lymphomas at the Society of Hematologic Oncology Annual Meeting
Published: 2023-08-31 (Crawled : 14:30) - biospace.com/
LTRN | $5.87 -2.0% 40K
|
Health Technology
|
| O: 0.21%
H: 1.05%
C: -4.84%
lp-284 pharma drug candidate lymphomas meeting
Lantern Pharma Expands AI Capabilities of RADR® Platform to Accelerate the Clinical Development of Immune Checkpoint Inhibitors
Published: 2023-08-28 (Crawled : 14:30) - biospace.com/
LTRN | $5.87 -2.0% 40K
|
Health Technology
|
| O: 0.42%
H: 0.0%
C: -3.12%
radr pharma platform
Lantern Pharma Receives Notice of US Patent Allowance for Drug Candidate LP-184 for the Treatment of Rare Pediatric Brain Cancer, ATRT
Published: 2023-08-14 (Crawled : 14:00) - biospace.com/
LTRN | $5.87 -2.0% 40K
|
Health Technology
|
| O: 2.04%
H: 0.0%
C: -4.0%
lp-184 rare pharma drug patent candidate treatment
Lantern Pharma to Report Second Quarter 2023 Operating & Financial Results on August 9, 2023 at 4:30 p.m. ET
Published: 2023-08-02 (Crawled : 13:00) - biospace.com/
LTRN | $5.87 -2.0% 40K
|
Health Technology
|
| O: -0.2%
H: 0.0%
C: -4.1%
pharma report financial results
Lantern Pharma to Participate and Present at Multiple Upcoming Conferences
Published: 2023-07-17 (Crawled : 13:00) - biospace.com/
LTRN | $5.87 -2.0% 40K
|
Health Technology
|
| O: 3.03%
H: 0.98%
C: -1.18%
pharma
Lantern Pharma Receives FDA Clearance of IND Application for Drug Candidate LP-184 in Solid Tumors
Published: 2023-06-12 (Crawled : 15:00) - biospace.com/
LTRN | $5.87 -2.0% 40K
|
Health Technology
|
| O: 3.7%
H: 4.46%
C: 4.11%
lp-184 fda pharma drug candidate tumors clearance application
Lantern Pharma Leverages AI Platform, RADR®, to Develop Breakthrough Antibody Drug Conjugates (ADCs) in Collaboration with Bielefeld University
Published: 2023-06-08 (Crawled : 16:00) - biospace.com/
LTRN | $5.87 -2.0% 40K
|
Health Technology
|
| O: 2.23%
H: 2.56%
C: 1.67%
radr pharma drug antibody collaboration
Lantern Pharma to Present at the Lytham Partners Spring 2023 Investor Conference Thursday, May 18th at 9:00 a.m. ET
Published: 2023-05-17 (Crawled : 14:00) - biospace.com/
LTRN | $5.87 -2.0% 40K
|
Health Technology
|
| O: 2.11%
H: 2.7%
C: 1.03%
pharma conference spring
Lantern Pharma Develops Top-Ranked AI Algorithms to Predict the Blood-Brain-Barrier Permeability of Any Compound
Published: 2023-05-02 (Crawled : 12:00) - biospace.com/
LTRN | $5.87 -2.0% 40K
|
Health Technology
|
| O: 1.51%
H: 0.34%
C: -1.49%
pharma
Lantern Pharma Receives Notice of Allowance for Composition of Matter Patent Covering Drug Candidate LP-284
Published: 2023-04-13 (Crawled : 12:20) - biospace.com/
LTRN | $5.87 -2.0% 40K
|
Health Technology
|
| O: 0.0%
H: 2.32%
C: 0.6%
lp-284 pharma drug patent candidate
Gainers vs Losers
| 83% | 17% |
Top 10 Gainers
AGBA | $0.7995 99.88% 73M
|
Finance
BPTH | $6.21 91.67% 58M
|
Health Technology
INVO | $1.36 78.95% 3.6M
|
Health Technology
TIRX | $0.8258 70.34% 50M
|
ISPC | $0.307 44.13% 3.6M
|
Professional, Scientific, and T...
SINT | $0.0504 35.12% 300M
|
Health Technology
VTNR S | $1.295 32.25% 5.5M
|
Industrial Services
ALRN | $5.53 30.12% 250K
|
Health Technology
SMSI 4 | $2.53 29.74% 510K
|
Technology Services
HOLO | $2.86 27.68% 28M
|
Your saved searches
Save your searches and get alerts when important news are released.